Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

被引：0
|
作者：
Qiu, Lugui [1 ,2 ]
Fu, Weijun [3 ]
Xia, Zhongjun [4 ]
Fu, Zhengzheng [5 ]
Chen, Wenming [6 ]
Chang, Chunkang [7 ]
Fang, Baijun [8 ]
An, Gang [1 ,2 ]
Wei, Yongqiang [9 ]
Cai, Zhen [10 ]
Gao, Sujun [11 ]
Weng, Jianyu [12 ]
Chen, Lijuan [13 ]
Jing, Hongmei [14 ]
Fei, Li [15 ]
Liu, Zhuogang [16 ]
Chen, Xiequn [17 ]
Liu, Jing [18 ]
Yu, Yang [19 ]
Wang, Aihua [19 ]
Yang, Yijun [19 ]
Yu, Zhinuan [19 ]
Lynch, Kevin [19 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
[3] Shanghai Chang Zheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[5] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
[6] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
[7] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China
[8] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[10] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China
[11] Jilin Univ, Hosp 1, Dept Hematol, Changchun, Peoples R China
[12] Guangdong Gen Hosp, Guangzhou, Peoples R China
[13] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China
[14] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[15] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[16] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China
[17] Air Force Med Univ, Xijing Hosp, Xian, Peoples R China
[18] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[19] Antengene Therapeut Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4770
引用
收藏
页数：5
相关论文
共 50 条
  • [21] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Corradini, Paolo
    Cavo, Michele
    Delforge, Michel
    Weisel, Katja C.
    Ocio, Enrique M.
    Di Raimondo, Francesco
    Hansson, Markus
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed H.
    Moreau, Philippe
    BLOOD, 2015, 126 (23)
  • [22] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [23] Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide-Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Handa, Hiroshi
    Suzuki, Kenshi
    Chou, Takaaki
    Matsushima, Takafumi
    BLOOD, 2014, 124 (21)
  • [24] ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)
    Weisel, K.
    Dimopoulos, M. A.
    Palumbo, A.
    Corradini, P.
    Cavo, M.
    Delforge, M.
    Ocio, E. M.
    Vacca, A.
    Hansson, M.
    Blanchard, M.
    Milller, N.
    Peluso, T.
    Sternas, L.
    Zaki, M.
    Moreau, P.
    HAEMATOLOGICA, 2015, 100 : 89 - 90
  • [25] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [26] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [27] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [28] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
    Grzasko, Norbert
    Knop, Stefan
    Goldschmidt, Hartmut
    Raab, Marc S.
    Durig, Jan
    Bringhen, Sara
    D'Agostino, Mattia
    Gamberi, Barbara
    Rivolti, Elena
    Vacca, Angelo
    Ria, Roberto
    Jurczyszyn, Artur
    Acosta, Jorge Castellano
    Lang, Doris
    Lemaillet, Guy
    Sudhir, Bansod
    Szarejko, Monika
    BLOOD, 2019, 134
  • [30] Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Alegria, Victoria R.
    Ahmed, Salman
    Laplant, Betsy
    Manna, Alak
    Parrondo, Ricardo
    Roy, Vivek
    Sher, Taimur
    Edwards, Brett
    Lanier, Stephanie
    Jackson, Keisha
    Chanan-Khan, Asher A.
    Paulus, Aneel
    BLOOD, 2019, 134
12345